Pacira BioSciences, Inc.
PCRX· Nasdaq
Released Nov 3, 2021, before the open
10-Q filed Nov 3, 2021, 34 days after period end · 0001396814-21-000063
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $127.72M | $117.48M | $104.35M | $82.71M |
| Net Income | $17.66M | $130.12M | -$6.09M | -$640.00K |
| EPS Diluted |
Pacira BioSciences, Inc. · CIK 1396814 · Engraved from SEC EDGAR
| $0.39 |
| $2.94 |
| -$0.15 |
| -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.